Zentalis Pharmaceuticals Inc (ZNTL)
$19.31
Market is closed - opens 7 PM, 04 Oct 2023
Insights on Zentalis Pharmaceuticals Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 66.6% return, outperforming this stock by 79.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 155.7% return, outperforming this stock by 195.2%
Performance
- $19.08$20.15$19.31
1.19%
Downside
Day's Volatility :5.31%
Upside
4.17%
- $15.55$31.46$19.31
19.47%
Downside
52 Weeks Volatility :50.57%
Upside
38.62%
Returns
| Period | Zentalis Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -30.99% | -3.2% | 0.0% |
6 Months | 10.41% | -2.7% | 0.0% |
1 Year | -13.02% | 0.8% | -0.4% |
3 Years | -44.91% | 22.3% | 14.9% |
Highlights
Market Capitalization | 1.9B |
Book Value | $7.41 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -4.87 |
Wall Street Target Price | 49.6 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -23.57% |
Return On Equity TTM | -57.29% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -222.9M |
Diluted Eps TTM | -4.87 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.82 |
EPS Estimate Next Year | -4.46 |
EPS Estimate Current Quarter | -1.04 |
EPS Estimate Next Quarter | -1.04 |
Analyst Recommendation
Buy
94%Buy
5%Hold
0
0%Sell
Based on 17 Wall street analysts offering stock ratings for Zentalis Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
- Current
- 1M Ago
- 3M Ago
Buy
16
16
16
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 156.86%
Current $19.31
Target $49.60
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Zentalis Pharmaceuticals Inc | -24.04% | 10.41% | -13.02% | -44.91% | -16.77% |
 Moderna, Inc. | -5.74% | -34.14% | -17.98% | 43.27% | 454.19% |
 Regeneron Pharmaceuticals, Inc. | -1.77% | -1.68% | 9.3% | 33.59% | 106.18% |
 Novo Nordisk A/s | -7.65% | 10.71% | 66.6% | 150.37% | 305.83% |
 Seagen, Inc. | 2.57% | 3.72% | 52.7% | 4.95% | 167.21% |
 Vertex Pharmaceuticals Incorporated | -0.89% | 9.77% | 14.81% | 28.32% | 82.99% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Zentalis Pharmaceuticals Inc | NA | NA | NA | -4.82 | -0.57 | -0.24 | 0.0 | 7.41 |
Moderna, Inc. | 34.44 | 34.44 | 0.0 | -3.45 | 0.07 | 0.01 | 0.0 | 44.49 |
Regeneron Pharmaceuticals, Inc. | 21.94 | 21.94 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
Novo Nordisk A/s | 43.71 | 43.71 | 2.03 | 1.66 | 0.82 | 0.22 | 0.01 | 2.52 |
Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
Vertex Pharmaceuticals Incorporated | 27.05 | 27.05 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Zentalis Pharmaceuticals Inc | Buy | $1.9B | -16.77% | NA | 0.0% |
Moderna, Inc. | Buy | $39.3B | 454.19% | 34.44 | 11.33% |
Regeneron Pharmaceuticals, Inc. | Buy | $88.8B | 106.18% | 21.94 | 33.93% |
Novo Nordisk A/s | Buy | $411.7B | 305.83% | 43.71 | 33.4% |
Seagen, Inc. | Hold | $39.7B | 167.21% | NA | -33.55% |
Vertex Pharmaceuticals Incorporated | Buy | $89.1B | 82.99% | 27.05 | 35.4% |
Institutional Holdings
Matrix Capital Management Company, LLC
19.77%FMR Inc
14.98%Eventide Asset Management, LLC
9.74%Vanguard Group Inc
6.98%BlackRock Inc
5.60%State Street Corporation
4.47%
Corporate Announcements
Zentalis Pharmaceuticals Inc Earnings
Zentalis Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
Organization | Zentalis Pharmaceuticals Inc |
Employees | 156 |
CEO | Dr. Kimberly Lynn Blackwell M.D. |
Industry | Health Technology |
